Literature DB >> 33144460

Axillary Clearance Following Positive Sentinel Lymph Node Biopsy in Symptomatic Breast Cancer.

Hudhaifah Shaker1, Zeinab Mahate1, Grit Dabritz1, Mohammed S Absar2.   

Abstract

BACKGROUND/AIM: Symptomatic cancers display a different biological behaviour from screen-detected cancers, which may impact the management of axillary metastases. We aimed to determine the role of unselected axillary nodal clearance (ANC) in symptomatic patients with positive sentinel node biopsies (SNBs). PATIENTS AND METHODS: A case-note review was performed on 95 symptomatic breast cancer patients who underwent ANC following positive SNB.
RESULTS: Thirty-eight (40%) patients were treated with a mastectomy and 57 (60%) with breast-conserving surgery. At ANC, 25 patients (26.3%) showed evidence of further lymph node metastases, with 15 (60%) having two or fewer macrometastases. The presence of more than 2 SNB macrometastases was associated with further ANC metastases (p<0.001). The presence of further metastases at ANC was not associated with either reduced overall survival or disease-free survival.
CONCLUSION: A number of symptomatic breast cancer patients with positive SNBs may be overtreated. Ongoing trials examining the management of low volume SNB macrometastases need to consider the symptomatic subgroup in their conclusions. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; axillary surgery; sentinel node biopsy; symptomatic breast cancer

Mesh:

Year:  2020        PMID: 33144460      PMCID: PMC7811626          DOI: 10.21873/invivo.12191

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

1.  POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases.

Authors:  A Goyal; D Dodwell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-08-05       Impact factor: 4.126

2.  Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.

Authors:  Á Sávolt; G Péley; C Polgár; N Udvarhelyi; G Rubovszky; E Kovács; B Győrffy; M Kásler; Z Mátrai
Journal:  Eur J Surg Oncol       Date:  2017-01-16       Impact factor: 4.424

3.  Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.

Authors:  Monica Morrow; Kimberly J Van Zee; Sujata Patil; Oriana Petruolo; Anita Mamtani; Andrea V Barrio; Deborah Capko; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Laurie Kirstein; Melissa Pilewskie; George Plitas; Virgilio S Sacchini; Lisa M Sclafani; Alice Ho; Hiram S Cody
Journal:  Ann Surg       Date:  2017-09       Impact factor: 12.969

4.  A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node.

Authors:  Gelareh Farshid; Malcolm Pradhan; James Kollias; P Grantley Gill
Journal:  Breast       Date:  2004-12       Impact factor: 4.380

5.  Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer.

Authors:  P G Gill; G Farshid; C G Luke; D M Roder
Journal:  Breast       Date:  2004-02       Impact factor: 4.380

6.  Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.

Authors:  D Grabau; L Dihge; M Fernö; C Ingvar; L Rydén
Journal:  Eur J Surg Oncol       Date:  2013-04-08       Impact factor: 4.424

7.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.

Authors:  Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

8.  Explaining the difference in prognosis between screen-detected and symptomatic breast cancers.

Authors:  P C Allgood; S W Duffy; O Kearins; E O'Sullivan; N Tappenden; M G Wallis; G Lawrence
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640

Review 9.  Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

Authors:  A Matikas; T Foukakis; S Swain; J Bergh
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

10.  Axillary treatment in women with one or two sentinel nodes with macrometastases: more evidence is needed to inform practice.

Authors:  Amit Goyal; David Dodwell; Malcolm W Reed; Robert E Coleman
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.